5 Apr 2023
THE LANCET Haematology: Sovleplenib for primary immune thrombocytopenia patients in China
THE LANCET :
FRESCO-2, a global Phase III study of fruquintinib in refractory metastatic colorectal cancer
Learn More
THE LANCET HAEMATOLOGY:
ESLIM-01 Phase III Study: Sovleplenib for primary immune thrombocytopenia patients in China
Learn More
THE LANCET Respiratory Medicine
Savolitinib Phase IIIb confirmatory study in treatment-naive METex14 NSCLC patients in China
Learn More
2024 Full Year Financial Results
Learn More
Latest News
31 Jul 2024HUTCHMED Reports 2024 Interim Results and Provides Business UpdatesRead more 4 Jul 2024HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review StatusRead more 26 Jun 2024HUTCHMED to Announce 2024 Half-Year Financial ResultsRead more
24 Jun 2024Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024Read more 22 Jun 2024HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by TakedaRead more 17 Jun 2024HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet HaematologyRead more 7 Jun 2024HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in ChinaRead more See all
Scientific Publications
17 Mar 2023
JSMO2023: Fruquintinib in Japanese patients with refractory metastatic CRC
2000
FOUNDED
HCM
NASDAQ &
LONDON AIM
LONDON AIM
13
HKEX
>20
NOVEL DRUG CANDIDATES
CREATED BY IN-HOUSE
DISCOVERY ENGINE
CREATED BY IN-HOUSE
DISCOVERY ENGINE
4
APPROVED & MARKETED
PRODUCTS IN CHINA
PRODUCTS IN CHINA
1
APPROVED & MARKETED
PRODUCT IN THE US, EU & JAPAN
PRODUCT IN THE US, EU & JAPAN
~40
CLINICAL TRIALS WORLDWIDE
INCLUDING 13+ REGISTRATION STUDIES
INCLUDING 13+ REGISTRATION STUDIES
>150,000
PATIENTS TREATED BY
OUR NOVEL MEDICINES
OUR NOVEL MEDICINES
OUR SCIENCE
Our core research and development philosophy is to take a holistic approach and treat cancer and immunological diseases through multiple modalities and mechanisms. We have taken a science-focused approach to develop highly selective, potent and well-tolerated cancer therapies that are deliberately engineered to improve drug exposure and reduce off-target toxicities.
FOLLOW HUTCHMED ON SOCIAL MEDIA
